Physician profile
Jonathan Mccoy
NPI 1700815313
$2,421.72
in general payments reported to CMS, 2019-2025
25 companies · $486 in 2025
The $486 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,075 · 2020: $236 · 2022: $31.41 · 2023: $214 · 2024: $379 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,078.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $405.75 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $349.45 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $310.53 | 2019-2025 | Breztri, Airsupra |
| Pfizer INC. | $218.14 | 2019-2025 | |
| Gilead Sciences, INC. | $156.56 | 2019-2025 | |
| Exact Sciences Corporation | $137.33 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $116.11 | 2019 | |
| Glaxosmithkline, LLC. | $114.99 | 2019-2025 | Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $61.69 | 2019 | |
| Sanofi-Aventis U.S. LLC | $60.69 | 2019-2020 | |
| Dexcom, INC. | $58.93 | 2024-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $49.40 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.19 | 2019 | |
| Abbvie INC. | $47.70 | 2023-2025 | |
| Abbott Laboratories | $42.54 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $38.80 | 2024 | Heplisav-B |
| Amgen INC. | $36.68 | 2019-2025 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $36.33 | 2019 | |
| Allergan, INC. | $25.14 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $19.67 | 2025 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $19.34 | 2019 | |
| Scilex Pharmaceuticals INC. | $19.09 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.71 | 2025 | Xifaxan |
| Sanofi Pasteur INC. | $15.66 | 2019 | |
| Daiichi Sankyo INC. | $14.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Mccoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.